Eko Health, Inc. Logo
<p><strong><span class="legendSpanClass"><span class="xn-location">SAN FRANCISCO</span></span></strong> &#8212; <u>Eko Health</u>, a pioneer in applying artificial intelligence for early detection of heart and lung diseases, has raised <span class="xn-money">$41 million</span> in Series D financing. With participation by ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital, the funding round will be used to expand U.S. and global access to the company&#8217;s early disease detection platform.</p>
<p>The funding builds on recent commercial and clinical milestones, including U.S.<a href="https://c212.net/c/link/?t=0&;l=en&;o=4183163-1&;h=2645134838&;u=https%3A%2F%2Fwww.ekohealth.com%2Fblogs%2Fnewsroom%2Feko-mobi-health-news-07202022&;a=%C2%A0" target="_blank" rel="nofollow noopener"> </a>FDA clearances for its <u><a href="https://c212.net/c/link/?t=0&;l=en&;o=4183163-1&;h=4125866054&;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Ffda-clears-ekos-heart-disease-detection-ai-for-adults-and-pediatrics-301583140.html&;a=structural+heart+murmur+" target="_blank" rel="nofollow noopener">structural heart murmur </a></u>and <u><a href="https://c212.net/c/link/?t=0&;l=en&;o=4183163-1&;h=2762077070&;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Ffda-clears-first-ai-to-aid-heart-failure-detection-during-routine-check-ups-302103718.html&;a=low+" target="_blank" rel="nofollow noopener">low </a><a href="https://c212.net/c/link/?t=0&;l=en&;o=4183163-1&;h=2627009297&;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Ffda-clears-first-ai-to-aid-heart-failure-detection-during-routine-check-ups-302103718.html&;a=ejection+fraction" target="_blank" rel="nofollow noopener">ejection fraction</a></u> (Low EF) detection algorithms. Eko&#8217;s murmur detection algorithm was clinically validated in a Massachusetts General Hospital <u><a href="https://c212.net/c/link/?t=0&;l=en&;o=4183163-1&;h=2330377000&;u=https%3A%2F%2Fwww.ahajournals.org%2Fdoi%2F10.1161%2Fcirc.148.suppl_1.13244&;a=study" target="_blank" rel="nofollow noopener">study</a></u> and found to double identification rates of structural heart murmurs versus conventional practice in primary care. The low EF detection algorithm, developed with Mayo Clinic, was shown in an Imperial College London <u><a href="https://c212.net/c/link/?t=0&;l=en&;o=4183163-1&;h=43576347&;u=https%3A%2F%2Fwww.imperial.ac.uk%2Fnews%2F232954%2Fartificial-intelligence-tool-could-help-gps%2F&;a=study" target="_blank" rel="nofollow noopener">study</a></u> to significantly enhance the identification of heart failure with reduced ejection fraction in GP clinics. By enhancing detection capabilities, Eko&#8217;s platform significantly reduces diagnostic bottlenecks, leading to earlier interventions and improved patient outcomes.</p>
<p>&#8220;Eko harnesses AI to unlock universal access to expert-level cardiac and pulmonary disease detection for patients everywhere,&#8221; said <span class="xn-person">Connor Landgraf</span>, CEO and co-founder of Eko Health. &#8220;Just as Ring transformed doorbells into home security systems, Eko has reinvented the world&#8217;s most ubiquitous medical tool into a powerful early disease detection platform, creating the world&#8217;s largest install base of professional AI-enabled cardiology devices.&#8221;</p>
<p>Cardiovascular and pulmonary diseases are among the<a href="https://c212.net/c/link/?t=0&;l=en&;o=4183163-1&;h=728250356&;u=https%3A%2F%2Fwww.who.int%2Fnews-room%2Ffact-sheets%2Fdetail%2Fthe-top-10-causes-of-death&;a=%C2%A0" target="_blank" rel="nofollow noopener"> </a><u><a href="https://c212.net/c/link/?t=0&;l=en&;o=4183163-1&;h=3254935542&;u=https%3A%2F%2Fwww.who.int%2Fnews-room%2Ffact-sheets%2Fdetail%2Fthe-top-10-causes-of-death&;a=leading+causes+of+death" target="_blank" rel="nofollow noopener">leading causes of death</a></u> worldwide, underscoring the critical need for early detection. Millions of patients remain<a href="https://c212.net/c/link/?t=0&;l=en&;o=4183163-1&;h=702693667&;u=https%3A%2F%2Fnewsroom.heart.org%2Fnews%2Fmore-than-half-of-u-s-adults-dont-know-heart-disease-is-leading-cause-of-death-despite-100-year-reign%23%3A%7E%3Atext%3DJanuary%252024%252C%25202024-%2CMore%2520than%2520half%2520of%2520U.S.%2520adults%2520don%2527t%2520know%2520heart%2Cdeath%252C%2520despite%2520100%252Dyear%2520reign%26text%3DHighlights%253A%2Cof%2520death%2520in%2520the%2520U.S.&;a=%C2%A0" target="_blank" rel="nofollow noopener"> </a><u><a href="https://c212.net/c/link/?t=0&;l=en&;o=4183163-1&;h=2436811045&;u=https%3A%2F%2Fnewsroom.heart.org%2Fnews%2Fmore-than-half-of-u-s-adults-dont-know-heart-disease-is-leading-cause-of-death-despite-100-year-reign%23%3A%7E%3Atext%3DJanuary%252024%252C%25202024-%2CMore%2520than%2520half%2520of%2520U.S.%2520adults%2520don%2527t%2520know%2520heart%2Cdeath%252C%2520despite%2520100%252Dyear%2520reign%26text%3DHighlights%253A%2Cof%2520death%2520in%2520the%2520U.S.&;a=unaware+of+their+risk" target="_blank" rel="nofollow noopener">unaware of their risk</a></u> factors, often due to limited access to effective detection tools. Eko is addressing this gap by introducing sophisticated detection capabilities into any physical exam — from primary care exams at <u><a href="https://c212.net/c/link/?t=0&;l=en&;o=4183163-1&;h=2820602797&;u=https%3A%2F%2Fnchmd.org%2Fpress-releases%2Fnch-is-first-healthcare-system-in-the-united-states-to-launch-fda-approved-sensora-cardiac-disease-detection-platform%2F&;a=NCH+Healthcare+System+" target="_blank" rel="nofollow noopener">NCH Healthcare System </a></u>in the U.S. to maternal-fetal health exams in <u><a href="https://c212.net/c/link/?t=0&;l=en&;o=4183163-1&;h=1144370185&;u=https%3A%2F%2Fwww.tctmd.com%2Fnews%2Fai-improves-detection-cardiomyopathy-pregnancy&;a=Nigeria" target="_blank" rel="nofollow noopener"><span class="xn-location">Nigeria</span></a></u>.</p>
<div class="pull-right inline-gallery-container col-md-8 col-sm-7 col-xs-12">
<div class="gallery inline-gallery">
<div class="row"></div>
</div>
</div>
<p>&#8220;Eko has spent the past decade building an unparalleled dataset of digital heart and lung sounds, which it leverages to develop clinical AI for the physical world,&#8221; said Vas Bailey, PhD, Chair of the Board at Eko Health and Partner at ARTIS Ventures. &#8220;Like countless others, I lost a parent much too early to undetected heart disease. I am deeply inspired by the team&#8217;s dedication to saving lives by equipping hundreds of thousands—and soon millions—of clinicians worldwide with our groundbreaking early detection platform.&#8221;</p>
<p>Eko will use the new capital to deepen its presence in the U.S. and accelerate its expansion into key international markets, supported by new strategic investments from Double Point Ventures in the U.S., <span class="xn-location">Singapore</span>-based global investor EDBI (the corporate investment arm of the Singapore Economic Development Board), and LG Technology Ventures, backed by the LG Group of <span class="xn-location">South Korea</span>. With the new funding and regulatory clearances, Eko is poised to rapidly expand access to its AI-enabled cardiac and pulmonary disease detection platform, empowering millions of healthcare professionals to improve patient outcomes in the coming years.</p>

SAN FRANCISCO -- Nirvana Insurance, an AI-native commercial insurer, has secured a preemptive $100 million…
SAN FRANCISCO -- Kargo, a provider of industrial artificial intelligence (AI) technology for supply chain…
The Federal Trade Commission announced that grocery delivery provider Instacart will pay $60 million in…
SANTA CLARA -- ServiceNow has agreed to buy Armis for $7.75 billion in cash. Armis…
The Nasdaq stock market has reformulated the list of 100 companies in the Nasdaq-100 Index…
NVIDIA says it has acquired SchedMD — the leading developer of Slurm, an open-source workload…